80.26 -0.56 (-0.69%)
After hours: 7:20PM EST
|Bid||79.02 x 800|
|Ask||81.58 x 800|
|Day's Range||77.56 - 83.75|
|52 Week Range||75.35 - 123.99|
|Beta (5Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||123.64|
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm ...
Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced that it has priced its underwritten public offering of 0.3750% convertible senior notes due 2028 (the "Notes") and upsized the offering from $850 million to $1.0 billion aggregate principal amount. The Company has granted the underwriter a 30-day option to purchase up to an additional $150.0 million aggregate principal amount of the Notes solely to cover over-allotments, if any.
Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $850 million aggregate principal amount of convertible senior notes due 2028 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $127.5 million aggregate principal amount of the Notes. The Company intends to use the net proceeds of this offering for general corporate purposes, which may include the repayment or repurchase of debt, working capital and possible acquisitions. The Notes will be convertible into cash, shares of the Company's common stock (and, if applicable, cash in lieu of any fractional share), or a combination thereof, at the Company's election.
Madison-based biotechnology company Exact Sciences Corp. is planning to grab a larger share of the $20 billion cancer diagnostic market with two more acquisitions. In an earnings call with analysts on Monday, CEO Kevin Conroy said his company, which makes the Cologuard take-home colon cancer screening test, had signed agreements to acquire Phoenix-area med tech companies Paradigm Diagnostics Inc. and Viomics. An estimated closing date for the acquisitions, or the financial details of the deals, were not disclosed.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...
Exact Sciences (EXAS) delivered earnings and revenue surprises of 0.00% and 0.40%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The company's fourth-quarter revenue, which is a 60% increase from the same quarter in 2018, is the combination of both Exact Sciences and Genomic Health, the California company Exact Sciences acquired last year in a $2.8 billion deal.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $295.6 million for the fourth quarter ended Dec. 31, 2019 and $876.3 million for the full year ended Dec. 31, 2019, including Precision Oncology revenue of $66.2 million for the period Nov. 8, 2019 through Dec. 31, 2019, following the close of the Genomic Health combination.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...
Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In 2015, Exact Sciences was approved by the WEDC to receive up to $9 million in tax credits if it added at least 750 jobs and made a capital investment of $26.2 million by 2020.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth-quarter and full-year 2019 financial results after the close of the U.S. financial markets on Feb. 11, 2020. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.